Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
March 06, 2023 07:00 ET
|
Passage Bio
Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial...
Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program
March 01, 2023 07:00 ET
|
Passage Bio
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or universityScholarship application deadline is April 1 for the initial...
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
February 28, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
February 27, 2023 07:00 ET
|
Passage Bio
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
February 24, 2023 07:00 ET
|
Passage Bio
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of PBGM01 led to a biological effect in patientsPBGM01 administration resulted...
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
February 15, 2023 07:00 ET
|
Passage Bio
– Updated interim data from first six patients in Phase 1/2 Imagine-1 study of PBGM01 for GM1 Gangliosidosis to be shared in oral platform and poster presentations PHILADELPHIA, Feb. 15, 2023 ...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 20, 2023 16:01 ET
|
Passage Bio
PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
December 14, 2022 07:00 ET
|
Passage Bio
Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in...
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022 07:00 ET
|
Passage Bio
Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-endPlan...
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
November 08, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...